Spots Global Cancer Trial Database for Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
Official Title: A Phase II Pilot Clinical Trial of Lurbinectedin (Zepzelca™ PM01183) in Patients With Gastrointestinal Malignancies With DNA Repair Mutations
Study ID: NCT05229588
Conditions
Interventions
Study Description
Brief Summary: The purpose of this research is to evaluate the activity and safety of lurbinectedin in adult patients with advanced Gastrointestinal Malignancies with DNA repair mutations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
Contact Details
Name: Erkut Borazanci, MD
Affiliation: HonorHealth Research Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
